Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Gilead Science’s twice-yearly shot for treating HIV prevented new infections by 96% among patients in a late-stage trial, ...

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

Gilead stock popped Thursday after the biotech giant said its twice-yearly shot prevented 99.9% of HIV infections in a study.

J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...

Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...

allowing it to extend the patent life of a blockbuster line of medications, internal documents show. By Rebecca Robbins and Sheryl Gay Stolberg A jury sided with Gilead Sciences in a dispute over ...

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset ...

Gilead Sciences’ shares closed up 2.7% at $83.16 yesterday, after it releases positive results of an interim analysis from a ...

Gilead Sciences and Genesis Therapeutics have entered a strategic collaboration to discover and develop novel small molecule ...

Jackson Egen learned the value of basic lab research as a graduate student at UC Berkeley in the 90s while working under the ...